3
Satoh, M. Miura, J. Org. Chem. 2014, 79, 7649. (f) N. Guimond,
S.-I. Gorelsky, K. Fagnou, J. Am. Chem. Soc. 2011, 133, 6449. (g)
F. W. Patureau, T. Besset, F. Glorius, Angew. Chem. Int. Ed. 2011,
50, 1064. (h) F. W. Patureau, F. Glorius, J. Am. Chem. Soc. 2010,
132, 9982.
(a) B. Li, J. Ma, N. Wang, H. Feng, S. Xu, B. Wang, Org. Lett.
2012, 14, 736. (b) L. Ackermann, L. Wang, R. Wolfram, A. V.
Lygin, Org. Lett. 2012, 14, 728. (c) Y. Hashimoto, T. Ueyama, T.
Fukutani, K. Hirano, T. Satoh, M. Miura, Chem. Lett. 2011, 40,
1165. (d) T. Ueyama, S. Mochida, T. Fukutani, K. Hirano, T. Satoh,
M. Miura, Org. Lett. 2011, 13, 706.
J, Kim, S.-W. Park, M.-H. Baik, S. Chang, J. Am. Chem. Soc. 2015,
137, 13448.
Y. Suzuki, B. Sun, T. Yoshino, S. Matsunaga, M. Kanai,
Tetrahedron 2015, 71, 4552.
B. M. Trost, Science 1991, 254, 1471.
P. A. Wender, B. L. Miller, Nature 2009, 460, 197.
give olefinated product 7ca with 87% ee (entry 7).
Interestingly, the reactivities of these anilides 4b and 4c
toward 6c were markedly higher than that of 4a, although the
precise reason cannot be explained at the present stage.
In conclusion, we have achieved the concise synthesis of
a fungal metabolite, (+)-fusarochromanone (FC-101), via the
oxidative sp2 C−H bond olefination of an N-acetyl
aminochromanone with a chiral functionalized electron-rich
4
alkene
catalyzed
by
an
(electron-deficient
η5-
cyclopentadienyl)rhodium(III) complex, [CpERhCl2]2, under
ambient conditions as a key step. This protocol was applied to
various acetanilides and functionalized electron-rich alkenes
for the synthesis of fusarochromanone analogs. Future work
will focus on further application of our CpERh(III)-catalyzed
oxidative sp2 C−H bond functionalization reactions to the key
step of the total synthesis of natural products or biologically
active compounds.
5
6
7
8
9
10
D.-H. Wang, J.-Q. Yu, J. Am. Chem. Soc. 2011, 133, 5767.
For selected recent reviews of the application of the transition-
metal-catalyzed C−H bond functionalization in total syntheses of
natural products or biologically active compounds, see: (a) J.
Yamaguchi, A. D. Yamaguchi, K. Itami, Angew. Chem. Int. Ed.
2012, 51, 8960. (b) D. Y.-K. Chen, S. W. Youn, Chem. Eur. J.
2012, 18, 9452. (c) W. R. Gutekunst, P. S. Baran, Chem. Soc. Rev.
2011, 40, 1976. (d) L. McMurray, F. O'Hara, M. J. Gaunt, Chem.
Soc. Rev. 2011, 40, 1885.
Q. Liu, Q. Li, Y. Ma, Y. Jia, Org. Lett. 2013, 15, 4528.
Y. Shibata, K. Tanaka, Angew. Chem. Int. Ed. 2011, 50, 10917.
Y. Takahama, Y. Shibata, K. Tanaka, Chem. Eur. J. 2015, 21, 9053.
Other examples of the rhodium(III)/CpE complex-catalyzed sp2
C−H bond functionalization, see: (a) Y. Hoshino, Y. Shibata, K.
Tanaka, Adv. Synth. Catal. 2014, 356, 1577. (b) M. Fukui, Y.
Hoshino, T. Satoh, M. Miura, K. Tanaka, Adv. Synth. Catal. 2014,
356, 1638.
Sterically and electronically tuned Cp ligands have been developed
to improve the reactivity and selectivity in the rhodium(III)-
catalyzed C–H bond functionalization. For [RhCl(cod)]2/C5H2Ph4,
see: (a) M. Shimizu, H. Tsurugi, T. Satoh, M. Miura, Chem. Asian
J. 2008, 3, 881. For Cpt [C5H3(t-Bu)2], see: (b) T. K. Hyster, T.
Rovis, Chem. Sci. 2011, 2, 1606. (c) T. K. Hyster, T. Rovis, Chem.
Commun. 2011, 47, 11846. For CpMe4 [C5HMe4], see: (d) R. Zeng,
J. Ye, C. Fu, S. Ma, Adv. Synth. Catal. 2013, 355, 1963. For CpiPr
[C5H4(i-Pr)], see: (e) T. Piou, T. Rovis, J. Am. Chem. Soc. 2014,
136, 11292. For [C5H3–(CH2)4–], see: (f) M. D. Wodrich, B. Ye, J.
F. Gonthier, C. Corminboeuf, N. Cramer, Chem. Eur. J. 2014, 20,
15409. For CpCF3 [C5Me4(CF3)], see: (g) J. M. Neely, T. Rovis, J.
Am. Chem. Soc. 2014, 136, 2735. (h) F. Romanov-Michailidis, K. F.
Sedillo, J. M. Neely, T. Rovis, J. Am. Chem. Soc. 2015, 137, 8892.
For Cp*Cy (C5Me4Cy) and Cp*tBu [C5Me4(t-Bu)], see: (i) T. Piou, T.
Rovis, Nature 2015, 527, 86. For Cp(CF3)2Ar {C5Me4[3,5-
(CF3)2C6H3]}, see: (j) T. A. Davis, C. Wang, T. Rovis, Synlett 2015,
26, 1520.
Isolation and structural determination of fusarochromanone, see:
(a) Y. W. Lee, C. J. Mirocha, D. J. Shroeder, M. M. Walser, Appl.
Environ. Microbiol. 1985, 50, 102. (b) S. V. Pathre, W. B. Gleason,
Y. W. Lee, C. J. Mirocha, Can. J. Chem. 1986, 64, 1308.
Toxicological and pharmacological studies of fusarochromanone,
see: (c) F. Minervini, G. Lucivero, A. Visconti, C. Bottalico, Nat.
Toxins 1992, 1, 15. (d) D. Dréau, M. Foster, M. Hogg, C.
Culberson, P. Nunes, R. E. Wuthier, Anticancer Drugs 2007, 18,
897. (e) E. Mahdavian, M. Marshall, P. M. Martin, P. Cagle, B. A.
Salvatore, Q. A. Quick, Int. J. Mol. Med. 2014, 34, 880.
B. A. Salvatore, F. C. Solis, PCT Int. Appl. WO 2004/103985,
2004.
This work was supported partly by ACT-C from the
Japan Science and Technology Agency (JST, Japan), Grants-
in-Aid for Scientific Research (Nos. 26102004 and 25105714)
from the Ministry of Education, Culture, Sports, Science and
Technology (MEXT, Japan), and a Grant-in-Aid for Research
Activity Start-up (No. 15H06201) from Japan Society for the
Promotion of Science (JSPS, Japan). We are grateful to
Umicore for generous support in supplying the rhodium
complex.
11
12
13
14
References and Notes
1
For selected resent reviews of the transition-metal catalyzed C–H
bond functionalization, see: (a) C. Liu, J. Yuan, M. Gao, S. Tang,
W. Li, R. Shi, A. Lei, Chem. Rev. 2015, 115, 12138. (b) S. De
Sarkar, W. Liu, S.-I. Kozhushkov, L. Ackermann, Adv. Synth.
Catal. 2014, 356, 1461. (c) L. Wang and J. Xiao, Adv. Synth. Catal.
2014, 356, 1137; (d) M. Miura, T. Satoh and K. Hirano, Bull. Chem.
Soc. Jpn. 2014, 87, 751; (e) L. Zhou, W. Lu, Chem. Eur. J. 2014,
20, 634. (f) Y. Wu, J. Wang, F. Mao, F.-Y. Kwong, Chem. Asian J.
2014, 9, 26. (g) S. I. Kozhushkov and L. Ackermann, Chem. Sci.
2013, 4, 886; (h) G. Song, F. Wang and X. Li, Chem. Soc. Rev.
2012, 41, 3651; (i) E. A. Mitchell, A. Peschiulli, N. Lefevre, L.
Meerpoel and B. U. W. Maes, Chem. Eur. J. 2012, 18, 10092; (j) P.
B. Arockiam, C. Bruneau and P. H. Dixneuf, Chem. Rev. 2012, 112,
5879; (k) C. S. Yeung and V. M. Dong, Chem. Rev. 2011, 111,
1215; (l) J. Wencel-Delord, T. Droege, F. Liu and F. Glorius, Chem.
Soc. Rev. 2011, 40, 4740; (m) C. Liu, H. Zhang, W. Shi and A. Lei,
Chem. Rev. 2011, 111, 1780; (n) S. H. Cho, J. Y. Kim, J. Kwak and
S. Chang, Chem. Soc. Rev. 2011, 40, 5068; (o) L. Ackermann,
Chem. Rev. 2011, 111, 1315; (p) T. Satoh and M. Miura, Chem.
Eur. J. 2010, 16, 11212; (q) D. A. Colby, R. G. Bergman and J. A.
Ellman, Chem. Rev. 2010, 110, 624; (r) E. M. Beccalli, G. Broggini,
A. Fasana and M. Rigamonti, J. Organomet. Chem. 2010, 696,
277; (s) P. Thansandote and M. Lautens, Chem. Eur. J. 2009, 15,
5874; (t) J. C. Lewis, R. G. Bergman and J. A. Ellman, Acc. Chem.
Res. 2008, 41, 1013.
(a) K.-J. Xiao, L. Chu, J.-Q. Yu, Angew. Chem. Int. Ed. 2016, 55,
2856. (b) H. Jiang, J. He, T. Liu, J.-Q. Yu, J. Am. Chem. Soc. 2016,
138, 2055. (c) S.-J. Han, H.-T. Kim, J.-M. Joo, J. Org. Chem. 2016,
81, 689. (d) M. Bera, A. Maji, S.-K. Sahoo, D. Maiti, Angew. Chem.
Int. Ed. 2015, 54, 8515. (e) J. Hu, M. Guan, J. Han, Z.-B. Huang,
D.-Q. Shi, Y. Zhao. J. Org. Chem. 2015, 80, 7896. (f) T. Katsina,
E.-E. Anagnostaki, F. Mitsa, V. Sarli, A.-L. Zografos, RSC Adv.
2016, 6, 6978. (g) G. Li, D. Leow, L. Wan, J.-Q. Yu, Angew. Chem.
Int. Ed. 2013, 52, 1245. (h) D. Leow, G. Li, T.-S. Mei, J.-Q. Yu,
Nature 2012, 486, 518. (i) M. Ye, G.-L. Gao, J.-Q. Yu, J. Am.
Chem. Soc. 2011, 133, 6964.
15
16
2
17
18
19
20
21
B. M. Trost, D. B. Horne, M. J. Woltering, Angew. Chem. Int. Ed.
2003, 42, 5987.
In sharp contrast, no reaction was observed by using [Cp*RhCl2]2
instead of 1.
M. Sova, J. Mravljak, A. Kovač, S. Pečar, Z. Časar, S. Gobec,
Synthesis 2010, 20, 3433.
The reaction of 4a and 6c resulted in low substrate conversions
(<40%), and a mixture of by-products were observed other than a
trace amount of the desired olefinated product 7ac.
3
(a) S.-M. Son, Y.-J. Seo, H.-K. Lee, Chem. Commun. 2016, 52,
4286. (b) Q. Jiang, C. Zhu, H. Zhao, W. Su, Chem. Asian J. 2016,
11, 356. (c) X.-H. Hu, X.-F. Yang, T.-P. Loh, Angew. Chem. Int.
Ed. 2015, 54, 15535. (d) A.-J. Borah, G. Yan, L. Wang, Eur. J. Org.
Chem. 2015, 2015, 4782. (e) Y. Yokoyama, Y. Unoh, K. Hirano, T.